Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic Review
| Authors: | Ganatra, S.; Dani, S. S.; Shah, S.; Asnani, A.; Neilan, T. G.; Lenihan, D.; Ky, B.; Barac, A.; Hayek, S. S.; Leja, M.; Herrmann, J.; Thavendiranathan, P.; Fradley, M.; Bang, V.; Shreyder, K.; Parikh, R.; Patel, R.; Singh, A.; Brar, S.; Guha, A.; Gupta, D.; Mascari, P.; Patten, R. D.; Venesy, D. M.; Nohria, A.; Resnic, F. S. |
| Review Title: | Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic |
| Abstract: | Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhythmia, and heart failure in patients without prior cardiovascular disease or significant risk factors, are emerging, possibly due to an accentuated host immune response and cytokine release syndrome. As the spread of the virus increases exponentially, many patients will require medical care either for COVID-19 related or traditional cardiovascular issues. While the COVID-19 pandemic is dominating the attention of the healthcare system, there is an unmet need for a standardized approach to deal with COVID-19 associated and other traditional cardiovascular issues during this period. We provide consensus guidance for the management of various cardiovascular conditions during the ongoing COVID-19 pandemic with the goal of providing the best care to all patients and minimizing the risk of exposure to frontline healthcare workers. © 2020 |
| Keywords: | review; outcome assessment; clinical practice; immunoglobulin; patient care; immune response; immunotherapy; cardiovascular disease; heart infarction; unstable angina pectoris; health care personnel; consensus development; antivirus agent; heart arrhythmia; medical care; drug contraindication; dipeptidyl carboxypeptidase inhibitor; hydroxymethylglutaryl coenzyme a reductase inhibitor; drug use; virus transmission; resuscitation; heart arrest; angiotensin receptor antagonist; venous thromboembolism; anticoagulant agent; extracorporeal oxygenation; antiviral therapy; antiinflammatory agent; cardiovascular effect; pandemic; plasma transfusion; cytokine release syndrome; acute coronary syndrome; qt interval; thrombosis prevention; coronavirus; cardiogenic shock; st segment elevation myocardial infarction; human; priority journal; heart muscle injury; non st segment elevation myocardial infarction; coronavirus disease 2019; sars-cov-2; covid-19, cardiovascular disease |
| Journal Title: | Trends in Cardiovascular Medicine |
| Volume: | 30 |
| Issue: | 6 |
| ISSN: | 1050-1738 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2020-08-01 |
| Start Page: | 315 |
| End Page: | 325 |
| Language: | English |
| DOI: | 10.1016/j.tcm.2020.05.004 |
| PUBMED: | 32474135 |
| PROVIDER: | scopus |
| PMCID: | PMC7255720 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
